

Table 3. Comparison of the efficacy of EVR+RTAC versus TAC control after 1, 2 and 3 years of study (ITT population).

Efficacy end point	De Simone 2012		Saliba 2013		Fischers 2015	
	EVR+RTAC arm (n=245)	TAC control arm (n=243)	EVR+RTAC arm (n=245)	TAC control arm (n=243)	EVR+RTAC arm (n=245)	TAC control arm (n=243)
Primary efficacy end point n (KM%)	16 (6.7)	23 (9.7)	24 (10.3)	29 (12.5)	26 (11.5)	32 (14.6)
Graft loss n (KM%)	6 (2.4)	3 (1.2)	9 (3.9)	7 (3.2)	9 (3.9)	8 (4.0)
Death n (KM%)	9 (3.7)	6 (2.5)	12 (5.2)	10 (4.4)	14 (6.5)	10 (4.4)
tBPAR n (KM%)	7 (2.9)	17 (7.0)	11 (4.8)	18 (7.7)	11 (4.8)	20 (9.2)
BPAR n (KM%)	10 (4.1)	26 (10.7)	14 (6.8)	30 (13.3)	15 (7.3)	34 (17.7)

KM Kaplan-Meier incidence